Shares in US biotech Checkpoint Therapeutics (Nasdaq: CKPT) slumped by nearly half on Monday.
The US biotech closed 45% lower after a day when the firm had announced a disappointing update on the skin cancer prospect cosibelimab, its lead product candidate.
"We believe we can address the feedback in a resubmission to enable marketing approval in 2024"It was revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the cosibelimab biologic license application (BLA) for the treatment of patients with metastatic or locally-advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze